Syndax Pharmaceuticals Inc ASH Annual Meeting Data Update Call Transcript
Good day, everyone, and welcome to the Syndax ASH Annual Meeting Data Update Call. Today's call is being recorded.
At this time, I would like to turn the call over to Michael Metzger, Chief Executive Officer of Syndax Pharmaceuticals.
Thank you, operator, and thanks to everyone joining us this morning to review our revumenib data presented yesterday in 2 oral presentations at the 64th ASH Annual Meeting.
I want to begin by pointing out our forward-looking statements on Slide 2. Before we review the Phase I data for revumenib, our highly selective menin inhibitor and hear from 2 of our principal investigators, I would like to take a moment to outline Syndax goals for this year's ASH meeting on Slide 3. Our team is first and foremost focused on physician engagement and our disease awareness campaign at ASH.
As leaders in the menin inhibitor field, we continue to build the awareness of the benefits of using a menin inhibitor to treat mutant NPM1 and KMT2A acute
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |